N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T hold diagnostic value in cardiac amyloidosis

Cardiac amyloidosis (CA) is associated with an elevation of natriuretic peptides and troponins, predicting outcome. Nevertheless, the diagnostic yield of these biomarkers has not been extensively investigated. This study aimed to evaluate the diagnostic performance for CA of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and high‐sensitivity troponin T (hs‐TnT).

[1]  M. Emdin,et al.  Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. , 2022, Journal of the American College of Cardiology.

[2]  M. Emdin,et al.  Biomarkers for the diagnosis and management of heart failure , 2021, Heart Failure Reviews.

[3]  U. Eriksson,et al.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.

[4]  M. Emdin,et al.  Use of biomarkers to diagnose and manage cardiac amyloidosis , 2021, European journal of heart failure.

[5]  M. Emdin,et al.  A simple echocardiographic score to rule out cardiac amyloidosis , 2020, European journal of clinical investigation.

[6]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[7]  M. Emdin,et al.  Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings , 2020, European journal of preventive cardiology.

[8]  A. Cohen-Solal,et al.  Diagnostic score of cardiac involvement in AL amyloidosis. , 2020, European heart journal cardiovascular Imaging.

[9]  G. Pontone,et al.  Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.

[10]  C. Rapezzi,et al.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.

[11]  M. Plebani,et al.  Evaluation of reproducibility of the cTnT immunoassay using quality control samples. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[12]  M. Woodward,et al.  Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. , 2018, Clinical chemistry.

[13]  Y. Izumiya,et al.  Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis , 2017, ESC heart failure.

[14]  A. Dispenzieri,et al.  Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response , 2017, Heart.

[15]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[16]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[17]  J. Deux,et al.  Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis , 2013, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[18]  A. Foli,et al.  Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure , 2012, American journal of hematology.

[19]  M. Emdin,et al.  Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[20]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[21]  A. Balduini,et al.  Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.

[22]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.